SEC ownership of Aptevo Therapeutics Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001671584.

Comparable stake leader

NIOWAVE, INC.

Disclosed value leader

YA II PN, Ltd.

Comparable rows

17/28

Latest evidence

25 May 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
17 of 28
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
NIOWAVE, INC.
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
25 May 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001671584
Issuer location
Seattle, WA

Ownership snapshot

Top shareholders of Aptevo Therapeutics Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
NIOWAVE, INC.
Disclosed value leader
YA II PN, Ltd.
Comparable rows
17/28
Latest evidence
25 May 2026
13D/G 3/4/5 13F Lead comparable stake: 12% 11 rows are not safely comparable across share classes. 13D/G row: NIOWAVE, INC. Showing 1-8 of 28 holder rows.

Quick read

NIOWAVE, INC. leads the comparable SEC ownership view at 12%.

17 of 28 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens NIOWAVE, INC.'s linked filing trail.
Comparable ownership Top 5
NIOWAVE, INC. 12%
Ayrton Capital LLC 10%
YA II PN, Ltd. 10%
BIGGER CAPITAL FUND L P 10%
CVI Investments, Inc. 8.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 28 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
NIOWAVE, INC.
13D/G 3/4/5
10%+ Owner
12%
$757,098
151,723 shares
$0 25 May 2026
Ayrton Capital LLC
13D/G
10%
$107,445
358,150 shares
$0 30 Jun 2025
YA II PN, Ltd.
13D/G
10%
$1,663,965
357,842 shares
$0 16 Jun 2025
BIGGER CAPITAL FUND L P
13D/G
10%
285,000 shares
$0 18 Jun 2025
CVI Investments, Inc.
13D/G
8.2%
$744,624
83,854 shares
$0 31 Dec 2025
L1 Capital Global Opportunities Master Fund, Ltd.
13D/G
5%
$492,900
164,300 shares
-$362,100 14 Aug 2025
Hudson Bay Capital Management LP
13D/G
5%
$52,853
76,598 shares
$0 31 Dec 2024
BANK OF AMERICA CORP /DE/
13D/G 3/4/5
10%+ Owner
0%
$125
86 shares
-$715,879 31 Oct 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$20,134.

Buys
$20,134
Insiders: 1
Sells
$0
Insiders: 0
Net
+$20,134
Shares: +13,513
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 13,513 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 13,513 0 $20,134 $0 +$20,134
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-15 of 15 reporting-owner rows connected to Aptevo Therapeutics Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
15
Largest Forms 3/4/5 holder
NIOWAVE, INC.
Net 12M change
+$20,134
Latest report
25 May 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
NIOWAVE, INC. 10%+ Owner $491,624 Mixed 25 May 2026
Grady Grant III Director $20,135 +$20,134 +2013400% Filing P/S 10 Nov 2025
BANK OF AMERICA CORP /DE/ 10%+ Owner $82 Mixed 01 Oct 2025
Marvin L. White President and CEO, Director $3 Market 06 Aug 2025
Jeffrey G. Lamothe Evp, Coo $1 Market 06 Aug 2025
SoYoung Kwon SVP, GC, BD & Corp Affairs $1 Market 06 Aug 2025
Daphne Taylor Svp, Cfo $0 Mixed 06 Aug 2025
Dirk Huebner Svp, Cmo $0 Mixed 06 Aug 2025
Barbara Lopez Kunz Director $0 Mixed 06 Aug 2025
Zsolt Harsanyi Director $0 Mixed 06 Aug 2025
John Niederhuber Director $0 Mixed 06 Aug 2025
Daniel Abdun-Nabi Director $0 Mixed 06 Aug 2025
Mary Jo Janatpour Svp, Cso $0 Mixed 20 May 2026
Fuad El-Hibri Director Mixed 03 Dec 2021
Kevin Tang Exit Filing Mixed 23 Nov 2021

Recent insider transactions for Aptevo Therapeutics Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Grady Grant III APVO Common Stock Purchase 1351300% $20,134 $1.49 13,513 13,514 10 Nov 2025 Direct
Daniel Abdun-Nabi APVO Restricted Stock Unit Award 7,200 7,200 06 Aug 2025 Direct
Daphne Taylor APVO Restricted Stock Unit Award 11,500 11,500 06 Aug 2025 Direct
Grady Grant III APVO Restricted Stock Unit Award 7,200 7,200 06 Aug 2025 Direct
Dirk Huebner APVO Restricted Stock Unit Award 11,500 11,500 06 Aug 2025 Direct
John Niederhuber APVO Restricted Stock Unit Award 7,200 7,200 06 Aug 2025 Direct
Jeffrey G. Lamothe APVO Restricted Stock Unit Award 17,300 17,300 06 Aug 2025 Direct
Marvin L. White APVO Restricted Stock Unit Award 30,000 30,000 06 Aug 2025 Direct
Barbara Lopez Kunz APVO Restricted Stock Unit Award 7,200 7,200 06 Aug 2025 Direct
SoYoung Kwon APVO Restricted Stock Unit Award 11,500 11,500 06 Aug 2025 Direct
Zsolt Harsanyi APVO Restricted Stock Unit Award 7,200 7,200 06 Aug 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .